Larimar Therapeutics (LRMR.US) Latest Stock News - Major News Analysis - Longbridge

Quote List Quote List

Event Tracking

Nov6

Larimar Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6091 (forecast USD -0.403)

04:00

Larimar Therapeutics released FY2025 9 Months Earnings on November 5, 2025 (EST), with actual revenue of USD 0 and EPS of USD -1.4758

04:00

Nov5

Larimar Therapeutics reports Q3 operating expenses of $49.5M

12:00

Oct14

Larimar Therapeutics Announces Positive Clinical Data for nomlabofusp for Friedreich's Ataxia

11:43

Oct8

Li Recommends Healthcare Stocks; Larimar Therapeutics Gets Buy Rating

11:41

Oct6

Wolleben Maintains Strong Buy Rating for Larimar Therapeutics, With a Target Price of $17.25

11:31

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -47.71 M, EPS -0.6091

Aug14

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -26.18 M, EPS -0.4089

Apr30

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -29.28 M, EPS -0.4577

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More